

List of Publications by Citations

Source: <https://exaly.com/author-pdf/8298880/cathy-eng-publications-by-citations.pdf>
Version: 2024-04-11

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

244 papers	13,140 citations	54 h-index	112 g-index
266 ext. papers	15,491 ext. citations	6.2 avg, IF	6.03 L-index

#	Paper	IF	Citations
244	Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. <i>Journal of Clinical Oncology</i> , 2006 , 24, 2065-72	2.2	1026
243	Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy. <i>Journal of Clinical Oncology</i> , 2009 , 27, 3677-83	2.2	955
242	Effect of surgical margin status on survival and site of recurrence after hepatic resection for colorectal metastases. <i>Annals of Surgery</i> , 2005 , 241, 715-22, discussion 722-4	7.8	805
241	EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2311-9	2.2	757
240	Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. <i>Journal of Clinical Oncology</i> , 2008 , 26, 5344-51	2.2	458
239	Phase II trial of infusional fluorouracil, irinotecan, and bevacizumab for metastatic colorectal cancer: efficacy and circulating angiogenic biomarkers associated with therapeutic resistance. <i>Journal of Clinical Oncology</i> , 2010 , 28, 453-9	2.2	383
238	A Practical Approach to the Management of Cancer Patients During the Novel Coronavirus Disease 2019 (COVID-19) Pandemic: An International Collaborative Group. <i>Oncologist</i> , 2020 , 25, e936-e945	5.7	356
237	Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. <i>Journal of Clinical Oncology</i> , 2017 , 35, 3240-3261	2.2	351
236	American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. <i>Journal of Clinical Oncology</i> , 2010 , 28, 493-508	2.2	340
235	Neoadjuvant treatment response as an early response indicator for patients with rectal cancer. <i>Journal of Clinical Oncology</i> , 2012 , 30, 1770-6	2.2	327
234	Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. <i>Cancer</i> , 2007 , 110, 2761-7	6.4	294
233	High survival rate after two-stage resection of advanced colorectal liver metastases: response-based selection and complete resection define outcome. <i>Journal of Clinical Oncology</i> , 2011 , 29, 1083-90	2.2	293
232	Predictors of tumor response and downstaging in patients who receive preoperative chemoradiation for rectal cancer. <i>Cancer</i> , 2007 , 109, 1750-5	6.4	247
231	Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study. <i>Lancet Oncology</i> , 2017 , 18, 446-453	21.7	223
230	Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial. <i>Lancet Oncology</i> , 2019 , 20, 849-861	21.7	201
229	Phase II study of capecitabine and oxaliplatin for advanced adenocarcinoma of the small bowel and ampulla of Vater. <i>Journal of Clinical Oncology</i> , 2009 , 27, 2598-603	2.2	167
228	A novel platform for detection of CK+ and CK- CTCs. <i>Cancer Discovery</i> , 2011 , 1, 580-6	24.4	162

227	Long-term results using local excision after preoperative chemoradiation among selected T3 rectal cancer patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2004 , 60, 1098-105	4	156
226	Phase II trial of neoadjuvant bevacizumab, capecitabine, and radiotherapy for locally advanced rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 76, 824-30	4	155
225	Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. <i>Journal of Clinical Oncology</i> , 2010 , 28, 2549-55	2.2	151
224	Predictors and patterns of recurrence after definitive chemoradiation for anal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007 , 68, 794-800	4	147
223	Classifying Colorectal Cancer by Tumor Location Rather than Sidedness Highlights a Continuum in Mutation Profiles and Consensus Molecular Subtypes. <i>Clinical Cancer Research</i> , 2018 , 24, 1062-1072	12.9	143
222	Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival. <i>Journal of Gastrointestinal Surgery</i> , 2007 , 11, 1498-504; discussion 1504-5	3.3	135
221	Clinical and pathologic predictors of locoregional recurrence, distant metastasis, and overall survival in patients treated with chemoradiation and mesorectal excision for rectal cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006 , 29, 219-24	2.7	128
220	Trends in colorectal cancer incidence by anatomic site and disease stage in the United States from 1976 to 2005. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011 , 34, 573-80	2.7	125
219	SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. <i>Investigational New Drugs</i> , 2012 , 30, 1646-51	4.3	120
218	Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains. <i>JAMA Surgery</i> , 2015 , 150, 402-9	5.4	107
217	Phase II study of capecitabine (Xeloda) and concomitant boost radiotherapy in patients with locally advanced rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2006 , 66, 762-71	4	102
216	Long-term quality of life after radiotherapy for the treatment of anal cancer. <i>Cancer</i> , 2010 , 116, 822-9	6.4	93
215	Liquid Biopsies Using Plasma Exosomal Nucleic Acids and Plasma Cell-Free DNA Compared with Clinical Outcomes of Patients with Advanced Cancers. <i>Clinical Cancer Research</i> , 2018 , 24, 181-188	12.9	89
214	Hyperfractionated accelerated radiotherapy for rectal cancer in patients with prior pelvic irradiation. <i>International Journal of Radiation Oncology Biology Physics</i> , 2010 , 77, 60-5	4	88
213	Long-term survival and recurrence outcomes following surgery for distal rectal cancer. <i>Annals of Surgical Oncology</i> , 2010 , 17, 2863-9	3.1	87
212	The association of alternate VEGF ligands with resistance to anti-VEGF therapy in metastatic colorectal cancer. <i>PLoS ONE</i> , 2013 , 8, e77117	3.7	84
211	Randomized phase Ib/II trial of rilotumumab or ganitumab with panitumumab versus panitumumab alone in patients with wild-type KRAS metastatic colorectal cancer. <i>Clinical Cancer Research</i> , 2014 , 20, 4240-50	12.9	83
210	ctDNA applications and integration in colorectal cancer: an NCI Colon and Rectal-Anal Task Forces whitepaper. <i>Nature Reviews Clinical Oncology</i> , 2020 , 17, 757-770	19.4	82

209	Modern systemic chemotherapy in surgically unresectable neoplasms of appendiceal origin: a single-institution experience. <i>Cancer</i> , 2010 , 116, 316-22	6.4	82
208	Clinical trial designs for rare diseases: studies developed and discussed by the International Rare Cancers Initiative. <i>European Journal of Cancer</i> , 2015 , 51, 271-81	7.5	80
207	Practical application of a calculator for conditional survival in colon cancer. <i>Journal of Clinical Oncology</i> , 2009 , 27, 5938-43	2.2	80
206	Deleterious Effect of RAS and Evolutionary High-risk TP53 Double Mutation in Colorectal Liver Metastases. <i>Annals of Surgery</i> , 2019 , 269, 917-923	7.8	78
205	Progression-free survival remains poor over sequential lines of systemic therapy in patients with BRAF-mutated colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2014 , 13, 164-71	3.8	77
204	Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program. <i>Journal of Clinical Oncology</i> , 2014 , 32, 2975-84	2.2	77
203	Oral alpha-lipoic acid to prevent chemotherapy-induced peripheral neuropathy: a randomized, double-blind, placebo-controlled trial. <i>Supportive Care in Cancer</i> , 2014 , 22, 1223-31	3.9	71
202	Metformin use and improved response to therapy in rectal cancer. <i>Cancer Medicine</i> , 2013 , 2, 99-107	4.8	70
201	The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal. <i>Oncotarget</i> , 2014 , 5, 11133-42	3.3	69
200	Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients with locally advanced pancreatic cancer. <i>Cancer</i> , 2010 , 116, 5325-35	6.4	67
199	Perifosine , an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012 , 8, 623-33	5.5	66
198	Serum exosomal miR-4772-3p is a predictor of tumor recurrence in stage II and III colon cancer. <i>Oncotarget</i> , 2016 , 7, 76250-76260	3.3	66
197	American Society of Clinical Oncology Statement: Human Papillomavirus Vaccination for Cancer Prevention. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1803-12	2.2	65
196	Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. <i>Clinical Cancer Research</i> , 2012 , 18, 3982-91	12.9	63
195	Antiemetics: ASCO Guideline Update. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2782-2797	2.2	63
194	Improving the AJCC/TNM staging for adenocarcinomas of the appendix: the prognostic impact of histological grade. <i>Annals of Surgery</i> , 2013 , 257, 1072-8	7.8	61
193	The current landscape of locally advanced rectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2011 , 8, 649-59	9.4	61
192	Lymph node status after neoadjuvant radiotherapy for rectal cancer is a biologic predictor of outcome. <i>Cancer</i> , 2009 , 115, 5432-40	6.4	59

191	Comprehensive Genomic Landscapes in Early and Later Onset Colorectal Cancer. <i>Clinical Cancer Research</i> , 2019 , 25, 5852-5858	12.9	58
190	Incidence, risk factors, and impact of severe neutropenia after hyperthermic intraperitoneal mitomycin C. <i>Annals of Surgical Oncology</i> , 2009 , 16, 2181-7	3.1	50
189	Intensity-modulated radiation therapy with concurrent chemotherapy for anal cancer: outcomes and toxicity. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014 , 37, 461-6	2.7	49
188	Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. <i>Nature Reviews Clinical Oncology</i> , 2009 , 6, 207-18	19.4	49
187	Association of SMAD4 mutation with patient demographics, tumor characteristics, and clinical outcomes in colorectal cancer. <i>PLoS ONE</i> , 2017 , 12, e0173345	3.7	49
186	Molecular biomarkers correlate with disease-free survival in patients with anal canal carcinoma treated with chemoradiation. <i>Digestive Diseases and Sciences</i> , 2010 , 55, 1098-105	4	48
185	Patterns of locoregional recurrence after surgery and radiotherapy or chemoradiation for rectal cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2008 , 71, 1175-80	4	48
184	A quantitative sensory analysis of peripheral neuropathy in colorectal cancer and its exacerbation by oxaliplatin chemotherapy. <i>Cancer Research</i> , 2014 , 74, 5955-62	10.1	47
183	Validation and application of a module of the M. D. Anderson Symptom Inventory for measuring multiple symptoms in patients with gastrointestinal cancer (the MDASI-GI). <i>Cancer</i> , 2010 , 116, 2053-63	6.4	47
182	Number of lymph nodes examined and prognosis among pathologically lymph node-negative patients after preoperative chemoradiation therapy for rectal adenocarcinoma. <i>Cancer</i> , 2011 , 117, 3713-22	6.4	46
181	Sacral insufficiency fractures after preoperative chemoradiation for rectal cancer: incidence, risk factors, and clinical course. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 74, 818-23	4	46
180	Perioperative systemic chemotherapy for appendiceal mucinous carcinoma peritonei treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. <i>Journal of Surgical Oncology</i> , 2014 , 109, 740-5	2.8	45
179	Evaluation of Prexasertib, a Checkpoint Kinase 1 Inhibitor, in a Phase Ib Study of Patients with Squamous Cell Carcinoma. <i>Clinical Cancer Research</i> , 2018 , 24, 3263-3272	12.9	41
178	Low-grade Appendiceal Mucinous Neoplasm of Uncertain Malignant Potential (LAMN-UMP): Prognostic Factors and Implications for Treatment and Follow-up. <i>Annals of Surgical Oncology</i> , 2017 , 24, 187-193	3.1	41
177	Subclinical peripheral neuropathy is a common finding in colorectal cancer patients prior to chemotherapy. <i>Clinical Cancer Research</i> , 2012 , 18, 3180-7	12.9	41
176	A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy. <i>International Journal of Cancer</i> , 2016 , 139, 177-86	7.5	40
175	A twenty-year experience with adenocarcinoma of the anal canal. <i>Diseases of the Colon and Rectum</i> , 2009 , 52, 1375-80	3.1	40
174	Impact of Recurrence and Salvage Surgery on Survival After Multidisciplinary Treatment of Rectal Cancer. <i>Journal of Clinical Oncology</i> , 2017 , 35, 2631-2638	2.2	39

173	GWAS-identified colorectal cancer susceptibility loci associated with clinical outcomes. <i>Carcinogenesis</i> , 2012 , 33, 1327-31	4.6	39
172	Quantified pathologic response assessed as residual tumor burden is a predictor of recurrence-free survival in patients with rectal cancer who undergo resection after neoadjuvant chemoradiotherapy. <i>Cancer</i> , 2013 , 119, 4231-41	6.4	39
171	FBXW7 missense mutation: a novel negative prognostic factor in metastatic colorectal adenocarcinoma. <i>Oncotarget</i> , 2017 , 8, 39268-39279	3.3	39
170	MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon. <i>Oncotarget</i> , 2016 , 7, 54627-54631	3.3	39
169	Global and targeted serum metabolic profiling of colorectal cancer progression. <i>Cancer</i> , 2017 , 123, 4066-4074	4.7	38
168	The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development. <i>Oncologist</i> , 2010 , 15, 73-84	5.7	38
167	Cetuximab in the treatment of patients with colorectal cancer. <i>Expert Opinion on Biological Therapy</i> , 2011 , 11, 937-49	5.4	38
166	Metastasis regulation by PPARD expression in cancer cells. <i>JCI Insight</i> , 2017 , 2, e91419	9.9	38
165	International Rare Cancers Initiative Multicenter Randomized Phase II Trial of Cisplatin and Fluorouracil Versus Carboplatin and Paclitaxel in Advanced Anal Cancer: InterAACT. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2510-2518	2.2	37
164	Comprehensive Genomic Profiling of Metastatic Squamous Cell Carcinoma of the Anal Canal. <i>Molecular Cancer Research</i> , 2017 , 15, 1542-1550	6.6	36
163	Randomized controlled trial of neurofeedback on chemotherapy-induced peripheral neuropathy: A pilot study. <i>Cancer</i> , 2017 , 123, 1989-1997	6.4	35
162	Postoperative chemotherapy use after neoadjuvant chemoradiotherapy for rectal cancer: Analysis of Surveillance, Epidemiology, and End Results-Medicare data, 1998-2007. <i>Cancer</i> , 2014 , 120, 1162-70	6.4	33
161	Anal cancer: current and future methodology. <i>Cancer Investigation</i> , 2006 , 24, 535-44	2.1	33
160	Hyperfractionated accelerated reirradiation for rectal cancer: An analysis of outcomes and toxicity. <i>Radiotherapy and Oncology</i> , 2017 , 122, 146-151	5.3	32
159	Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin. <i>Oncotarget</i> , 2016 , 7, 67495-67506	3.3	32
158	Association of CHFR promoter methylation with disease recurrence in locally advanced colon cancer. <i>Clinical Cancer Research</i> , 2011 , 17, 4531-40	12.9	31
157	Impact of molecular alterations and targeted therapy in appendiceal adenocarcinomas. <i>Oncologist</i> , 2013 , 18, 1270-7	5.7	30
156	Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. <i>Clinical Cancer Research</i> , 2017 , 23, 4146-4154	12.9	29

155	Cell-free Circulating Tumor DNA Variant Allele Frequency Associates with Survival in Metastatic Cancer. <i>Clinical Cancer Research</i> , 2020 , 26, 1924-1931	12.9	26
154	Clinicopathologic Features Associated With Human Papillomavirus/p16 in Patients With Metastatic Squamous Cell Carcinoma of the Anal Canal. <i>Oncologist</i> , 2015 , 20, 1247-52	5.7	26
153	The Treatment of Colorectal Cancer During Pregnancy: Cytotoxic Chemotherapy and Targeted Therapy Challenges. <i>Oncologist</i> , 2016 , 21, 563-70	5.7	26
152	The promise of mTOR inhibitors in the treatment of colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2012 , 21, 1775-88	5.9	23
151	Intensity-modulated radiation therapy for the treatment of squamous cell anal cancer with para-aortic nodal involvement. <i>International Journal of Radiation Oncology Biology Physics</i> , 2009 , 75, 791-4	4	23
150	Bevacizumab in the treatment of a patient with metastatic colorectal carcinoma with brain metastases. <i>Clinical Colorectal Cancer</i> , 2008 , 7, 65-8	3.8	23
149	Long-term results of weekly/daily cisplatin-based chemoradiation for locally advanced squamous cell carcinoma of the anal canal. <i>Cancer</i> , 2013 , 119, 3769-75	6.4	22
148	A phase 1 study of hepatic arterial infusion of oxaliplatin in combination with systemic 5-fluorouracil, leucovorin, and bevacizumab in patients with advanced solid tumors metastatic to the liver. <i>Cancer</i> , 2010 , 116, 4086-94	6.4	22
147	Clinical utility of circulating cell-free DNA in advanced colorectal cancer. <i>PLoS ONE</i> , 2017 , 12, e0183949	3.7	21
146	The Long-Term Impact of Neurofeedback on Symptom Burden and Interference in Patients With Chronic Chemotherapy-Induced Neuropathy: Analysis of a Randomized Controlled Trial. <i>Journal of Pain and Symptom Management</i> , 2018 , 55, 1276-1285	4.8	21
145	Prechemotherapy Touch Sensation Deficits Predict Oxaliplatin-Induced Neuropathy in Patients with Colorectal Cancer. <i>Oncology</i> , 2016 , 90, 127-35	3.6	20
144	Consensus statement on essential patient characteristics in systemic treatment trials for metastatic colorectal cancer: Supported by the ARCAD Group. <i>European Journal of Cancer</i> , 2018 , 100, 35-45	7.5	20
143	First-in-human trial of multikinase VEGF inhibitor regorafenib and anti-EGFR antibody cetuximab in advanced cancer patients. <i>JCI Insight</i> , 2017 , 2,	9.9	19
142	Role of immune checkpoint inhibitors in the treatment of colorectal cancer: focus on nivolumab. <i>Expert Opinion on Biological Therapy</i> , 2019 , 19, 1247-1263	5.4	19
141	Proteomic Features of Colorectal Cancer Identify Tumor Subtypes Independent of Oncogenic Mutations and Independently Predict Relapse-Free Survival. <i>Annals of Surgical Oncology</i> , 2017 , 24, 4051-4058	3.1	19
140	Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Moderately and Poorly Differentiated Appendiceal Adenocarcinoma: Survival Outcomes and Patient Selection. <i>Annals of Surgical Oncology</i> , 2017 , 24, 2646-2654	3.1	19
139	Preoperative radiation therapy with concurrent capecitabine, bevacizumab, and erlotinib for rectal cancer: a phase 1 trial. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014 , 88, 301-5	4	17
138	Treatment options in metastatic squamous cell carcinoma of the anal canal. <i>Current Treatment Options in Oncology</i> , 2008 , 9, 400-7	5.4	17

137	Short course radiation as a component of definitive multidisciplinary treatment for select patients with metastatic rectal adenocarcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2017 , 8, 990-997	2.8	16
136	Comparison of early radiological predictors of outcome in patients with colorectal cancer with unresectable hepatic metastases treated with bevacizumab. <i>Gut</i> , 2018 , 67, 1095-1102	19.2	16
135	Chemotherapy and radiation of anal canal cancer: the first approach. <i>Surgical Oncology Clinics of North America</i> , 2004 , 13, 309-20, viii	2.7	16
134	Epidermal growth factor receptor inhibition in metastatic anal cancer. <i>Anti-Cancer Drugs</i> , 2016 , 27, 804-824	8.4	16
133	Survival benefit associated with surgical oophorectomy in patients with colorectal cancer metastatic to the ovary. <i>Clinical Colorectal Cancer</i> , 2012 , 11, 191-4	3.8	15
132	Systematic survey of therapeutic trials for metastatic colorectal cancer: room for improvement in the critical pathway. <i>Journal of Clinical Oncology</i> , 2008 , 26, 2000-5	2.2	15
131	Prognostic factors for squamous cell cancer of the anal canal. <i>Gastrointestinal Cancer Research: GCR</i> , 2008 , 2, 10-4		15
130	Definitive Chemoradiation for Squamous Cell Carcinoma of the Rectum. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017 , 40, 163-166	2.7	14
129	Measurement of DNA damage in peripheral blood by the γ H2AX assay as predictor of colorectal cancer risk. <i>DNA Repair</i> , 2017 , 53, 24-30	4.3	14
128	Signet ring cell colorectal cancer: genomic insights into a rare subpopulation of colorectal adenocarcinoma. <i>British Journal of Cancer</i> , 2019 , 121, 505-510	8.7	14
127	Preoperative radiation dose escalation for rectal cancer using a concomitant boost strategy improves tumor downstaging without increasing toxicity: A matched-pair analysis. <i>Advances in Radiation Oncology</i> , 2017 , 2, 455-464	3.3	13
126	Fatal diffuse alveolar damage associated with oxaliplatin administration. <i>Clinical Colorectal Cancer</i> , 2011 , 10, 198-202	3.8	13
125	Models to Predict Hepatitis B Virus Infection Among Patients With Cancer Undergoing Systemic Anticancer Therapy: A Prospective Cohort Study. <i>Journal of Clinical Oncology</i> , 2018 , 36, 959-967	2.2	13
124	Oncologic and Functional Hazards of Obesity Among Patients With Locally Advanced Rectal Cancer Following Neoadjuvant Chemoradiation Therapy. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2017 , 40, 277-282	2.7	12
123	Impact of the timing of hepatitis B virus identification and anti-hepatitis B virus therapy initiation on the risk of adverse liver outcomes for patients receiving cancer therapy. <i>Cancer</i> , 2017 , 123, 3367-3376	6.4	12
122	Minocycline for Symptom Reduction During Oxaliplatin-Based Chemotherapy for Colorectal Cancer: A Phase II Randomized Clinical Trial. <i>Journal of Pain and Symptom Management</i> , 2019 , 58, 662-671	4.8	12
121	Preoperative chemotherapy prior to pulmonary metastasectomy in surgically resected primary colorectal carcinoma. <i>Oncotarget</i> , 2014 , 5, 6584-93	3.3	12
120	The Management and Prevention of Anal Squamous Cell Carcinoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019 , 39, 216-225	7.1	11

119	Are herbal medicines ripe for the cancer clinic?. <i>Science Translational Medicine</i> , 2010 , 2, 45ps41	17.5	11
118	Interactions between cigarette smoking and selected polymorphisms in xenobiotic metabolizing enzymes in risk for colorectal cancer: A case-only analysis. <i>Molecular Carcinogenesis</i> , 2010 , 49, 974-80	5	11
117	Extended-Field Chemoradiation Therapy for Definitive Treatment of Anal Canal Squamous Cell Carcinoma Involving the Para-Aortic Lymph Nodes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018 , 102, 102-108	4	11
116	Identification of polymorphisms in ultraconserved elements associated with clinical outcomes in locally advanced colorectal adenocarcinoma. <i>Cancer</i> , 2012 , 118, 6188-98	6.4	10
115	Identification of Novel Transcriptome Signature as a Potential Prognostic Biomarker for Anti-Angiogenic Therapy in Glioblastoma Multiforme. <i>Cancers</i> , 2020 , 12,	6.6	10
114	Role of Chemotherapy in the Neoadjuvant/Adjuvant Setting for Patients With Rectal Adenocarcinoma Undergoing Chemoradiotherapy and Surgery or Radiotherapy and Surgery. <i>Current Oncology Reports</i> , 2018 , 20, 3	6.3	9
113	Hyperfractionated Accelerated Reirradiation for Patients With Recurrent Anal Cancer Previously Treated With Definitive Chemoradiation. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018 , 41, 632-637	2.7	9
112	Role of Immunotherapy in the Treatment of Squamous Cell Carcinoma of the Anal Canal. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2018 , 16, 903-908	7.3	9
111	Atypical metastatic presentations in colorectal cancer: a case series. <i>Clinical Colorectal Cancer</i> , 2014 , 13, e1-4	3.8	9
110	Total Transthoracic Approach Facilitates Laparoscopic Hepatic Resection in Patients with Significant Prior Abdominal Surgery. <i>Annals of Surgical Oncology</i> , 2017 , 24, 1376-1377	3.1	9
109	Multidetector computed tomography follow-up of hypoattenuating small liver lesions in patients with rectal cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2011 , 34, 411-6	2.7	9
108	Emerging drugs for colorectal cancer. <i>Expert Opinion on Emerging Drugs</i> , 2008 , 13, 629-42	3.7	9
107	Neoadjuvant Strategies: Locally Advanced Rectal Cancer. <i>Clinics in Colon and Rectal Surgery</i> , 2017 , 30, 383-386	2.3	8
106	Physician interpretation of genomic test results and treatment selection. <i>Cancer</i> , 2018 , 124, 966-972	6.4	8
105	Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019). <i>European Journal of Surgical Oncology</i> , 2020 , 46, 955-966	3.6	7
104	POLE mutations in colorectal cancer: a new biomarker?. <i>The Lancet Gastroenterology and Hepatology</i> , 2016 , 1, 176-177	18.8	7
103	Utility of Appendiceal Calcifications Detected on Computed Tomography as a Predictor for an Underlying Appendiceal Epithelial Neoplasm. <i>Annals of Surgical Oncology</i> , 2017 , 24, 3667-3672	3.1	7
102	Retrospective study of nonmucinous appendiceal adenocarcinomas: role of systemic chemotherapy and cytoreductive surgery. <i>BMC Cancer</i> , 2017 , 17, 331	4.8	7

101	Genomic analysis and selected molecular pathways in rare cancers. <i>Physical Biology</i> , 2012 , 9, 065004	3	7
100	A comprehensive framework for early-onset colorectal cancer research.. <i>Lancet Oncology</i> , 2022 , 23, 1021-1031	21.7	7
99	Minimally invasive management of the entire treatment sequence in patients with stage IV colorectal cancer: a propensity-score weighting analysis. <i>Hpb</i> , 2018 , 20, 1150-1156	3.8	6
98	Optimal management of squamous cell carcinoma of the anal canal: where are we now?. <i>Expert Review of Anticancer Therapy</i> , 2014 , 14, 877-86	3.5	6
97	Metastatic Anal Cancer and Novel Agents. <i>Surgical Oncology Clinics of North America</i> , 2017 , 26, 133-142	2.7	6
96	Potential Prognostic Impact of Baseline CEA Level and Surgery of Primary Tumor Among Patients with Synchronous Stage IV Colorectal Cancer: A Large Population Based Study. <i>Indian Journal of Surgical Oncology</i> , 2015 , 6, 198-206	0.7	6
95	Role of the MET/IGF axis in colorectal cancer: precepts and prospects. <i>Colorectal Cancer</i> , 2012 , 1, 329-340	1.8	6
94	Second-line chemotherapy use in metastatic colon cancer varies by disease responsiveness. <i>Clinical Colorectal Cancer</i> , 2008 , 7, 55-9	3.8	6
93	A phase II study of axalimogene filolisbac for patients with previously treated, unresectable, persistent/recurrent loco-regional or metastatic anal cancer. <i>Oncotarget</i> , 2020 , 11, 1334-1343	3.3	6
92	Summary of emerging targets in anal cancer: the case for an immunotherapy based-approach. <i>Journal of Gastrointestinal Oncology</i> , 2016 , 7, 721-726	2.8	6
91	Sleep disturbance in patients with cancer: a feasibility study of multimodal therapy. <i>BMJ Supportive and Palliative Care</i> , 2021 , 11, 170-179	2.2	6
90	Evolution of Cancer Care in Response to the COVID-19 Pandemic. <i>Oncologist</i> , 2020 , 25, e1426-e1427	5.7	5
89	Optimal treatment strategies for anal cancer. <i>Current Treatment Options in Oncology</i> , 2014 , 15, 443-55	5.4	5
88	Cetuximab in refractory squamous cell carcinoma of the anal canal. <i>Journal of Gastrointestinal Cancer</i> , 2014 , 45 Suppl 1, 198-200	1.6	5
87	The current state of targeted agents in rectal cancer. <i>International Journal of Surgical Oncology</i> , 2012 , 2012, 406830	0.9	5
86	Atypical, Non-V600 BRAF Mutations as a Potential Mechanism of Resistance to EGFR Inhibition in Metastatic Colorectal Cancer. <i>JCO Precision Oncology</i> , 2019 , 3, 1-10	3.6	5
85	K-Ras and sensitivity to EGFR inhibitors in metastatic colorectal cancer. <i>Clinical Advances in Hematology and Oncology</i> , 2008 , 6, 174-5	0.6	5
84	Quality of life after intensity-modulated radiation therapy for anal cancer. <i>Journal of Radiation Oncology</i> , 2015 , 4, 291-298	0.7	4

83	Early-Onset Appendiceal Cancer Survival by Race or Ethnicity in the United States. <i>Gastroenterology</i> , 2020 , 159, 1605-1608	13.3	4
82	Pharmacotherapy of Anal Cancer. <i>Drugs</i> , 2017 , 77, 1519-1530	12.1	4
81	Genetic variants within ultraconserved elements and susceptibility to right- and left-sided colorectal adenocarcinoma. <i>Carcinogenesis</i> , 2012 , 33, 841-7	4.6	4
80	Definitive chemoradiation in oligometastatic squamous cell carcinoma of the anal canal. <i>Gastrointestinal Cancer Research: GCR</i> , 2014 , 7, 65-8		4
79	Cetuximab in combination with cisplatin and 5-Fluorouracil induces dramatic response in metastatic refractory squamous cell carcinoma of the anal canal. <i>Journal of Gastrointestinal Oncology</i> , 2015 , 6, E82-5	2.8	4
78	First-in-human PET imaging and estimated radiation dosimetry of L-[5-C]-glutamine in patients with metastatic colorectal cancer. <i>Journal of Nuclear Medicine</i> , 2021 ,	8.9	4
77	The prognostic impact of RAS on overall survival following liver resection in early versus late-onset colorectal cancer patients. <i>British Journal of Cancer</i> , 2021 , 124, 797-804	8.7	4
76	Moving Beyond the Momentum: Innovative Approaches to Clinical Trial Implementation. <i>JCO Oncology Practice</i> , 2021 , 17, 607-614	2.3	4
75	Spectrum of Somatic Cancer Gene Variations Among Adults With Appendiceal Cancer by Age at Disease Onset. <i>JAMA Network Open</i> , 2020 , 3, e2028644	10.4	4
74	Circulating DNA biomarkers: a primer for metastatic colorectal cancer?. <i>Lancet Oncology, The</i> , 2015 , 16, 878-9	21.7	3
73	Treatment of primary rectal adenocarcinoma after prior pelvic radiation: The role of hyperfractionated accelerated reirradiation. <i>Advances in Radiation Oncology</i> , 2018 , 3, 595-600	3.3	3
72	Up-and-Coming Experimental Drug Options for Metastatic Colorectal Cancer. <i>Journal of Experimental Pharmacology</i> , 2020 , 12, 475-485	3	3
71	Outcomes with anti-EGFR monoclonal antibodies in metastatic and recurrent anal squamous cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2020 , 20, 901-908	3.5	3
70	Identification of Actionable Genomic Alterations Using Circulating Cell-Free DNA. <i>JCO Precision Oncology</i> , 2019 , 3,	3.6	3
69	Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second-Line Treatment for Patients with Metastatic Colorectal Cancer. <i>Oncologist</i> , 2021 , 26, e261-e269	5.7	3
68	Challenges of efficacy assessments in pseudomyxoma peritonea. <i>Oncologist</i> , 2015 , 20, e3-4	5.7	2
67	FOLFOXIRI Versus Doublet Regimens in Right-Sided Metastatic Colorectal Cancer: Focus on Subsequent Therapies and Impact on Overall Survival. <i>Clinical Colorectal Cancer</i> , 2020 , 19, 248-255.e6	3.8	2
66	More questions regarding HIPEC in colorectal carcinomatosis. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 744-745	18.8	2

65	Pathologic complete response in poorly differentiated adenocarcinomas of the appendix: a case series. <i>Acta Oncologica</i> , 2013 , 52, 1044-6	3.2	2
64	Commentary: practice patterns and potential impact on quality measures for a practicing physician. <i>Journal of Oncology Practice</i> , 2009 , 5, 233-5	3.1	2
63	Biological agents versus chemotherapy in the treatment of colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2006 , 7, 1251-71	4	2
62	Intensity-modulated radiation therapy (IMRT) with concurrent chemotherapy for anal cancer: A large single-institution experience.. <i>Journal of Clinical Oncology</i> , 2012 , 30, 661-661	2.2	2
61	Trends in the Incidence and Treatment of Early-Onset Pancreatic Cancer.. <i>Cancers</i> , 2022 , 14,	6.6	2
60	Management of refractory metastatic anal squamous cell carcinoma following disease progression on traditional chemoradiation therapy. <i>Journal of the Advanced Practitioner in Oncology</i> , 2012 , 3, 161-9	0.7	2
59	Integrated clinico-molecular profiling of appendiceal adenocarcinoma reveals a unique grade-driven entity distinct from colorectal cancer. <i>British Journal of Cancer</i> , 2020 , 123, 1262-1270	8.7	2
58	Surgical resection and survival outcomes in metastatic young adult colorectal cancer patients. <i>Cancer Medicine</i> , 2021 , 10, 4269-4281	4.8	2
57	Current synthetic pharmacotherapy for treatment-resistant colorectal cancer: when urgent action is required. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 523-534	4	2
56	Experimental and investigational drugs for the treatment of anal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2018 , 27, 941-950	5.9	2
55	Genetic susceptibility markers for a breast-colorectal cancer phenotype: Exploratory results from genome-wide association studies. <i>PLoS ONE</i> , 2018 , 13, e0196245	3.7	2
54	The promise of immunotherapy in anal squamous cell carcinoma: a novel approach for an orphan disease. <i>Clinical Advances in Hematology and Oncology</i> , 2017 , 15, 968-961	0.6	2
53	Overall Survival in Phase 3 Clinical Trials and the Surveillance, Epidemiology, and End Results Database in Patients With Metastatic Colorectal Cancer, 1986-2016. <i>JAMA Network Open</i> , 2022 , 5, e2213588	10.4	2
52	Total Laparoscopic Management for Stage IV Colorectal Cancer Requiring Multivisceral Resection. <i>Annals of Surgical Oncology</i> , 2017 , 24, 2595	3.1	1
51	Pharmacotherapeutic considerations for elderly patients with colorectal cancer. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 2139-2160	4	1
50	Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low C and improved tolerability, in patients with solid tumors. <i>Investigational New Drugs</i> , 2020 , 38, 1763-1773	4.3	1
49	TAS-102 plus bevacizumab: a new standard for metastatic colorectal cancer?. <i>Lancet Oncology</i> , 2020 , 21, 326-327	21.7	1
48	Multidisciplinary management of stage IV colon cancer. <i>Seminars in Colon and Rectal Surgery</i> , 2016 , 27, 213-218	0.3	1

47	A Phase II Study of Capecitabine/Oxaliplatin With Concurrent Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Anal Canal. <i>Clinical Colorectal Cancer</i> , 2019 , 18, 301-306	3.8	1
46	Controversies in Adjuvant Chemotherapy 2014 , 177-199		1
45	Management of Adenomas 2014 , 51-65		1
44	Should cisplatin be avoided in the treatment of locally advanced squamous cell carcinoma of the anal canal?. <i>Nature Reviews Gastroenterology & Hepatology</i> , 2009 , 6, 16-7		1
43	Combining targeted therapies to enhance the effectiveness of chemotherapy in patients with treatment-refractory colorectal cancer. <i>Clinical Colorectal Cancer</i> , 2007 , 6 Suppl 2, S53-9	3.8	1
42	The natural history and role of surgical cytoreduction and systemic chemotherapy in high-grade mucinous adenocarcinomas of the appendix.. <i>Journal of Clinical Oncology</i> , 2013 , 31, 199-199	2.2	1
41	Perspectives on clinical trials for gastrointestinal malignancies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2015 , 40-3	7.1	1
40	Reply to S. Boutayeb et al. <i>JCO Oncology Practice</i> , 2020 , 16, 525	2.3	1
39	Anal cancer treatment regimen considerations for the COVID-19 era: In regard to Tchelebi et al. <i>Radiotherapy and Oncology</i> , 2020 , 151, 56-57	5.3	1
38	FRESCO-2: a global Phase III study investigating the efficacy and safety of fruquintinib in metastatic colorectal cancer. <i>Future Oncology</i> , 2021 , 17, 3151-3162	3.6	1
37	The treatment of colorectal carcinoma: standard chemotherapy and beyond. <i>Clinical Advances in Hematology and Oncology</i> , 2004 , 2, 592-8	0.6	1
36	Targeted Fibroblast Growth Factor Receptor (FGFR) Inhibition in Recurrent, Metastatic Anal Carcinoma: A Case Report.. <i>Clinical Colorectal Cancer</i> , 2022 ,	3.8	0
35	Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution.. <i>Oncologist</i> , 2022 , 27, 40-47	5.7	0
34	Age-standardised incidence rate and epidemiology of colorectal cancer in Africa: a systematic review and meta-analysis.. <i>BMJ Open</i> , 2022 , 12, e052376	3	0
33	Safety considerations with new treatment regimens for anal cancer. <i>Expert Opinion on Drug Safety</i> , 2021 , 20, 889-902	4.1	0
32	CEA as a blood-based biomarker in anal cancer. <i>Oncotarget</i> , 2021 , 12, 1037-1045	3.3	0
31	Colorectal cancer during pregnancy or postpartum: Case series and literature review. <i>Obstetric Medicine</i> , 1753495X2110412	1.5	0
30	Cutaneous Lymphangitic Carcinomatosis as the First Sign of Recurrent Malignancy in a Patient With a History of Rectal Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2021 ,	3.8	0

- 29 Colorectal Cancer Survivorship Management **2015**, 71-93
- 28 In Reply. *Oncologist*, **2020**, 25, e1252-e1253 5.7
- 27 Bevacizumab Does Not Influence the Efficacy of Partial Splenic Embolization in the Management of Chemotherapy-Induced Hypersplenism. *Clinical Colorectal Cancer*, **2020**, 19, e189-e199 3.8
- 26 Anal Cancer **2018**, 149-162
- 25 Long- Versus Short-Course Radiotherapy for Rectal Cancer **2014**, 200-217
- 24 Will PICCOLO affect metastatic colorectal cancer therapy?. *Lancet Oncology, The*, **2013**, 14, 679-80 21.7
- 23 Controversies in Advanced Disease [Surgical Approaches for Metastatic Resection **2014**, 227-242
- 22 What is the Role of Surveillance for Colorectal Cancer? **2014**, 261-271
- 21 Surgery for Anal Cancer **2014**, 163-176
- 20 How Histopathology Affects the Management of the Multidisciplinary Team **2014**, 67-83
- 19 Neoadjuvant Therapy Without Surgery for Early Stage Rectal Cancer? **2014**, 126-149
- 18 Minimally Invasive Surgery for Rectal Cancer and Robotics **2014**, 150-162
- 17 The Young Patient with Colorectal Cancer [Genetic Counseling Discussion **2014**, 273-285
- 16 Palliative Care Vignettes **2014**, 292-297
- 15 More Treatment is not Necessarily Better [Limited Options for Chemotherapeutic Radiosensitization **2014**, 218-226
- 14 Best Practices of Supportive Care While Receiving Chemotherapy **2014**, 286-291
- 13 Controversies in Chemotherapy in Advanced Colorectal Cancer **2014**, 243-260
- 12 Radical Colonic Resection **2014**, 85-103

11	Extralevator AbdominoPerineal Excision (ELAPE) for Advanced Low Rectal Cancer 2014 , 104-125	
10	Clinical Implications of Circulating Tumor Cells in Advanced Colorectal Cancer. <i>Current Colorectal Cancer Reports</i> , 2012 , 8, 233-242	1
9	Journal Watch: Our panel of experts highlight the most important research articles across the spectrum of topics relevant to the field of colorectal cancer. <i>Colorectal Cancer</i> , 2012 , 1, 15-16	0.8
8	Aggressive combined modality therapy for recurrent colorectal cancer involving the duodenum and pancreas: a report of 5 cases. <i>Clinical Colorectal Cancer</i> , 2008 , 7, 338-42	3.8
7	Managing Non-Hepatic Metastatic Sites: Lung and CNS 2019 , 495-508	
6	Squamous Cell Carcinoma of the Anal Canal 2019 , 175-184	
5	Immunotherapy for GI Cancers: Who Benefits, Who Does Not, and Promising Strategies to Expand Use. <i>Advances in Oncology</i> , 2021 , 1, 283-295	
4	Colorectal cancer adjuvant chemotherapy trends among a nonelderly veteran cohort at a southern veterans health administration. <i>Cancer Reports</i> , 2021 , e1508	1.5
3	Squamous Cell Carcinoma of the Anal Verge with Sigmoid Colon Metastasis. <i>Clinical Colorectal Cancer</i> , 2021 , 20, e210-e213	3.8
2	Carcinoma of the anal canal: small steps in treatment advances. <i>Clinical Advances in Hematology and Oncology</i> , 2011 , 9, 662-9	0.6
1	Clinical and pathologic features correlated with rare favorable survival in patients with mutated colorectal cancer.. <i>Journal of Gastrointestinal Oncology</i> , 2022 , 13, 647-656	2.8